Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.
Exploring the companies and themes that make up this emerging and exciting new sector
New York Lawmakers Discuss Competing Psychedelics Reform Bills Ahead Of Key Deadline
With just a month left before the end of New York’s legislative session, lawmakers sponsoring differing psychedelics reform legislation recently participated in a discussion on the path forward for psilocybin in the Empire State.
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
Pharmather announces receiving a patent from the USPTO for its "ketamine flow synthesis". Pharmather has exclusive worldwide development and commercial rights to this IP.
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
Mydecine announces raising $1,693,434.60 in addition to gross proceeds of $333,333.35 announced on March 22, 2022.
Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highlights
Wesana reports its Q4 2021 financial results and announces closing of a financing.
Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results
Awakn Life Sciences reports fourth quarter and full-year results for its fiscal year ending January 31, 2022. Annual revenues of CAD$236,037.
Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility
Optimi Health announces the opening of Canada's largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.
Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M
Incannex Healthcare announces a "shareholder loyalty option" to raise A$23.6 million (US$16.5 million). For every two shares purchased, investors will receive a "piggyback option".
Is The Psychedelic Drug Industry Entering A New Phase?
Several major new deals in the psychedelics industry already in 2022 suggest that the industry could be moving on to its next phase of evolution.
TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL
Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.
Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies
Field Trip announces its corporate decision to separate Field Trip Health and Field Trip Discovery into separate companies.
Is Minera Alamos Revolutionizing Gold Mining For The 21st Century?
Minera Alamos' "new" model for successful gold mining in the 21st century has a very retro flair to it.